36 results about "Pharmacological interventions" patented technology

The invention discloses a wearable / handheld personal communication device with hardware and software sensor modules that sense and analyze all caregiver prescribed / monitored user-lifestyle activities, and deploys such analysis in improving user's overall health in terms of reduced risks for all-cause morbidities / mortalities and eventually a life without drugs. Termed Rx Zero, such method may be prescribed not just for maintaining a healthy lifestyle, but for treatment of chronic diseases with intent to wean the patients to minimal or zero pharmacological intervention, or in combination with medications to improve prognosis of the disease under treatment.The benefits of the Rx Zero method of the present invention extend not only to the individual and the community through high quality healthcare at lower cost, but payers by reducing the loss ratio on account of reduced cost of medical claims, and to the caregivers in terms of an effective tool that disseminates, implements and redefines “Primary Health Care” and “Prevention” at levels beyond the terms' currently understood scope that has transformed healthcare to sickcare.

Systemic suppression of the complement system has been shown to be effective to treat inflammatory disease, yet at the potential cost of compromising host defense and immune homeostasis. Herein disclosed are methods for antigen-specific targeting of complement inhibitors that show that complement inhibitors targeted to the proximal tubular epithelium protect against tubulointerstitial injury and renal dysfunction in a rat model of nephrosis. It is shown that appropriate targeting of a systemically administered complement inhibitor to a site of disease markedy enhances efficacy and obviates the need to systemically inhibit complement. Additionally, it is shown by specifically inhibiting the terminal pathway of complement, that the membrane attack complex (MAC) plays a key role in proteinuria-induced tubulointerstitial injury, thus establishing the MAC as a valid target for pharmacological intervention in proteinuric disorders. The disclosed are compositions can be used in methods of treating pathogenic diseases and inflammatory conditions by modulating the complement system.

The present invention includes methods of modulating cellular secretory processes. More specifically the present invention relates to modulating or reducing the release of inflammatory mediators from inflammatory cells by inhibiting the mechanism associated with the release of inflammatory mediators from the vesicles or granules in the inflammatory cells. In this regard, the present invention discloses an intracellular signaling mechanism that illustrates several novel intracellular targets for pharmacological intervention in disorders involving secretion of inflammatory mediators from vesicles in inflammatory cells. MANS peptide and active fragments thereof are useful in such methods.

The present invention relates to pharmacological interventions with pemafibrate for moderate or severe hypertriglyceridemia.

The invention relates to the use of corticotropin-releasing hormone (CRH) receptor-1 (R1) antagonists and / or CRH-R2 receptor agonists for the treatment of inflammatory diseases via regulation of monocyte / macrophage cell activation, proliferation, differentiation, apoptosis, and inflammatory cytokine production. As CRH system we define natural and synthetic CRH and urocortin (UCN) agonists and antagonists for the CRH-R1 and CRH-R2 receptors and their subtypes as well as the CRH-binding protein (BP), a CRH pseudo-receptor. The invention is directed towards pharmacological intervention for the amelioration or treatment of inflammatory diseases using the CRH system-mediated control of monocyte / macrophage cells which play a key role in initiating and maintaining the inflammatory response via production of pro-inflammatory cytokines such as is the interleukin (IL)-1, IL-6 and tumor necrosis factor (TNF)-alpha. By the term inflammation we define the response of an organism to noxious endogenous or exogenous stimuli causing tissue injury. Inflammation is a host defence mechanism, which might harm the defending organism. The invention also provides methods for the in vitro and in vivo evaluation of natural and synthetic CRH system modulators for the control of the monocyte / macrophage system.

The present invention provides pharmacological interventions for the treatment of dyslipidemia, and to the reduction of residual risk of cardiovascular disease and adverse cardiovascular events in patients on intense statin use or with well-controlled LDL-C concentrations. In particular, the invention relates to the use of pemafibrate to prevent cardiovascular events in populations at-risk due to risk factors such as type 2 diabetes mellitus with dyslipidemia in spite of intense statin use or well-controlled LDL-C.

The invention discloses a method for evaluating antimicrobial activity of andrographis paniculata. According to the method, the antimicrobial activity of andrographis paniculata is evaluated by antibacterial rate I%, wherein the I% is calculated according to the following formula (1):I%=(t2-t0) / t0*100%(1), t0 refers to the time to peak of a second exponential growth phase in a growth and metabolism thermogram of bacteria which is not subjected to pharmacological intervention, t2 refers to the time to peak of a second exponential growth phase in a growth and metabolism thermogram of bacteria which is subjected to intervention of andrographis paniculata, and the concentration of a test solution of the andrographis paniculata interfering growth and metabolism of the bacteria ranges from 0.4mg / mL to 4 mg / mL, preferably 3mg / mL. The method provided by the invention can be used for qualitatively analyzing the antimicrobial activity of andrographis paniculata produced in different production areas, different preparation methods, different production batches or different growth time, and the like.

The present invention relates to a pharmaceutical composition for treating and repairing spinal cord injury and its application. The present invention finds through research that Rab3A plays a key role in SCI, and interacts with Spastin to regulate neurite outgrowth. By identifying proteins that were differentially expressed in SCI, it was demonstrated that Rab3A expression levels were downregulated during SCI. In addition, it was also found that Rab3A can physically interact with Spastin and regulate Spastin degradation through the lysosomal pathway, thereby affecting Spastin function. Collectively, these findings highlight a signal transduction pathway in which Rab3A-mediated spastin degradation regulates neurite branch formation and growth. Since SCI is a major cause of disability, repairing the structural defects of the spinal cord caused by injury or degeneration is crucial in the modern field of regenerative medicine. A variety of pharmacological interventions can be designed to treat SCI and assist with associated tissue repair, and can be combined with other cellular interventions.

The invention discloses asiaticoside, and a function of a pharmaceutically acceptable derivative thereof in bone metabolic abnormality. The asiaticoside has an adjustment function on simultaneously inhibiting osteoclast formation under the situation of bone metabolic abnormality, is low in effective dosage, and has a better effect on adjusting bone metabolic abnormality. The invention defines an intervention way of an asiaticoside related drug. The invention clarifies that a molecular mechanism in a bone microenvironment and a potential pharmacology intervention way are crucial to identifyinga novel treatment compound.